Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

Back

Evaluation of the QuantiFERON-TB Test.

NCT02253537·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

QIAGEN Gaithersburg, Inc

To compare the sensitivity of the CST001 assay to the QuantiFERON-TB Gold assay in patients with bacteriologically confirmed and untreated TB disease.

Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Clinical symptoms consistent with a high probability of having TB disease
Receiving, or are likely to receive, therapy for active TB
Confirmed tuberculosis by either AFB smear and culture testing, or Nucleic Acid Amplification methods and culture testing.
Between 18 and 70 years of age.

You may not be if

Taken therapy for active TB or latent TB for more than 14 days
Culture confirmation of M. tuberculosis not obtained

The record

StatusCompleted

PhaseNo phase

Taking part15

StartedFeb 2015

UpdatedJun 18, 2019

Conditions

Tuberculosis

Where1

University of Washington
Seattle, Washington, United States

Clareo Health | Evaluation of the QuantiFERON-TB Test.